Oxyntomodulin
Oxyntomodulin is a glucagon receptor agonist in the GLP-1 Agonist class. Oxyntomodulin is produced from proglucagon in intestinal L cells and comprises the glucagon sequence plus an eight-residue C-terminal extension.
For research use only.
Key Facts
- CAS
- 62340-29-8
- Molecular Weight (MW)
- 4422 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Naturally occurring 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors. It is the endogenous template for the dual-agonist drug class and is studied rather than marketed. Not FDA-approved.
Peptide Library's Oxyntomodulin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C192H295N59O60S |
|---|---|
| Molecular weight | 4422 g/mol |
| CAS number | 62340-29-8 |
| PubChem CID | 16144019 |
| ChEMBL | CHEMBL2401865 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Oxyntomodulin is produced from proglucagon in intestinal L cells and comprises the glucagon sequence plus an eight-residue C-terminal extension. It is a relatively weak agonist at both the GLP-1 and glucagon receptors compared with the native ligand of each, but engaging both simultaneously combines GLP-1-mediated appetite suppression and insulin secretion with glucagon-mediated increases in energy expenditure. This combination is the pharmacological rationale behind engineered dual agonists such as cotadutide and survodutide.
Studies
- Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
- Unraveling oxyntomodulin, GLP1's enigmatic brother
- Proglucagon-derived peptides: human physiology and therapeutic potential
- Gut hormones and appetite regulation
- Physiological Appetite Regulation and Bariatric Surgery
Regulatory & research status
Oxyntomodulin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Oxyntomodulin: frequently asked questions
What is Oxyntomodulin?
Naturally occurring 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors. It is the endogenous template for the dual-agonist drug class and is studied rather than marketed. Not FDA-approved.
How does Oxyntomodulin work?
Oxyntomodulin is produced from proglucagon in intestinal L cells and comprises the glucagon sequence plus an eight-residue C-terminal extension. It is a relatively weak agonist at both the GLP-1 and glucagon receptors compared with the native ligand of each, but engaging both simultaneously combines GLP-1-mediated appetite suppression and insulin secretion with glucagon-mediated increases in energy expenditure.
Is Oxyntomodulin FDA approved?
No. Oxyntomodulin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Oxyntomodulin?
Compounds most often compared with Oxyntomodulin include Retatrutide, Survodutide, Pemvidutide and Cotadutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity — Peptides, 2023External reference
- Unraveling oxyntomodulin, GLP1's enigmatic brother — J Endocrinol, 2012External reference
- Proglucagon-derived peptides: human physiology and therapeutic potential — Physiol Rev, 2026External reference
- Gut hormones and appetite regulation — Curr Opin Endocrinol Diabetes Obes, 2024External reference
- Physiological Appetite Regulation and Bariatric Surgery — J Clin Med, 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Oxyntomodulin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Oxyntomodulin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →